Compounds > butamirate
Page last updated: 2024-09-22

butamirate

Description

butamirate: RN, N1 & SY refer to citrate salt; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28891
CHEMBL ID2106133
SCHEMBL ID636120
MeSH IDM0049635
PubMed CID28892
CHEMBL ID1332546
CHEBI ID135310
SCHEMBL ID668881
MeSH IDM0049635

Synonyms (99)

Synonym
2-(2-(diethylamino)ethoxy)ethyl 2-phenylbutyrate citrate (1:1)
butamyrate citrate
hh-197
alpha-ethylbenzeneacetic acid 2-(2-(diethylamino)ethoxy)ethyl ester citrate
phenyl acetic acid diethylaminoethoxyethanol ester citrate
sincodex
einecs 242-006-8
sinecod
abbott 36581
sincodix
butamirate citrate
acodeen
alpha-ethylbenzeneacetic acid, 2-(2-(diethylamino)ethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
benzeneacetic acid, alpha-ethyl-2-(2-(diethylamino)ethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
butamirate citrate [usan]
2-(2-(diethylamino)ethoxy)-ethyl 2-phenylbutyrate citrate
2-phenylbutyric acid 2-(2-(diethylamino)ethoxy)ethyl ester citrate
diethyl(2-(2-(2-phenylbutyroyloxy)ethoxy)ethyl)ammonium dihydrogencitrate
sincodeen
sincodin
hh 197
butyric acid, 2-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate
18109-81-4
butamirate citrate (usan)
D03184
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutanoate 2-hydroxypropane-1,2,3-tricarboxylate (salt)
STK069532
FT-0663922
unii-67hp51l98r
67hp51l98r ,
abbott-36581
dtxcid8026270
cas-18109-81-4
dtxsid0046270 ,
tox21_111952
CHEMBL2106133
AKOS005390008
SCHEMBL636120
NCGC00160645-02
tox21_111952_1
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutyrate citrate (1:1)
butamirate citrate [mi]
butamirate citrate [mart.]
butamirate citrate [who-dd]
benzeneacetic acid, .alpha.-ethyl-2-(2-(diethylamino)ethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
J-011560
BCP22355
FT-0663923
butamirate (citrate)
Q27264132
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutanoate;2-hydroxypropane-1,2,3-tricarboxylic acid
alpha-(ethyl)benzeneacetic acid 2-[2-(diethylamino)ethoxy]ethyl ester
oxeladin impurity d
benzeneacetic acid, alpha-ethyl-, 2-[2-(diethylamino)ethoxy]ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
2-(2-(diethylamino)ethoxy)ethyl 2-phenylbutanoate citrate
butamirate
18109-80-3
butamirate (inn)
codimin (tn)
D07594
MLS001047521
smr000425405
2-phenyl-butyric acid 2-(2-diethylamino-ethoxy)-ethyl ester; compound with 3-carboxy-3-hydroxy-pentanedioic acid
CHEBI:135310
brospamin
butamirato [inn-spanish]
benzeneacetic acid, alpha-ethyl-, 2-(2-(diethylamino)ethoxy)ethyl ester
butamirate [inn:ban]
butamiratum
unii-m75mzg2236
butamirato
ec 242-005-2
m75mzg2236 ,
einecs 242-005-2
butamiratum [inn-latin]
butamyrate
codimin
CHEMBL1332546
AKOS015969721
HMS2784H23
SCHEMBL668881
2-(2-(diethylamino)ethoxy)ethyl 2-phenylbutyrate
butamirate [inn]
benzeneacetic acid, .alpha.-ethyl-2-(2-(diethylamino)ethoxy)ethyl ester
butamirate [who-dd]
butamirate [mi]
DTXSID7048403
benzeneacetic acid, .alpha.-ethyl-, 2-[2-(diethylamino)ethoxy]ethyl ester
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutyrate
DDVUMDPCZWBYRA-UHFFFAOYSA-N
FT-0696983
butamirat
2-(2- diethylaminoethoxy)ethyl-2-phenylbutyrat
DB13731
2-[2-(diethylamino)ethoxy]ethyl 2-phenylbutanoate
Q2360598
18109-80-3 (free base)
CS-0066328
HY-118545

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency5.95690.000811.382244.6684AID686979
cytochrome P450 2D6Homo sapiens (human)Potency10.96400.00108.379861.1304AID1645840
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency12.58930.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (17.65)18.7374
1990's5 (14.71)18.2507
2000's3 (8.82)29.6817
2010's12 (35.29)24.3611
2020's8 (23.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials6 (23.08%)5.53%
Reviews0 (0.00%)6.00%
Reviews2 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (7.69%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other16 (61.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
sorbic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
sorbic acid
alpha-cyclodextrin[no description available]medium10cyclodextrin
benzoic acid[no description available]medium10benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
ambroxol[no description available]medium21aromatic amine
ketotifen[no description available]medium10cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
tetraborate[no description available]medium10
propylparaben[no description available]medium10benzoate ester;
paraben;
phenols		antifungal agent;
antimicrobial agent
oxeladin[no description available]medium10alkylbenzene
diphenhydramine hydrochloride[no description available]medium155hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
dextromethorphan[no description available]medium116-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
capsaicin[no description available]medium11capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
bradykinin[no description available]medium11oligopeptidehuman blood serum metabolite;
vasodilator agent
histamine[no description available]medium11aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
morphine[no description available]medium11morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
citric acid, anhydrous[no description available]medium10tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
medigoxin[no description available]medium10cardenolide glycoside
triamterene[no description available]medium10pteridinesdiuretic;
sodium channel blocker
medazepam[no description available]medium10organic molecular entity
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
verapamil[no description available]medium10aromatic ether;
nitrile;
polyether;
tertiary amino compound
hydrochlorothiazide[no description available]medium10benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
2-phenylbutyric acid[no description available]medium11benzenes;
monocarboxylic acid		human xenobiotic metabolite
phenyltoloxamine[no description available]medium11diarylmethane
codeine[no description available]medium21morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
clobutinol[no description available]medium11benzenes;
organic amino compound
zipeprol[no description available]medium10benzyl ether
guaifenesin[no description available]medium10methoxybenzenes
tyrphostin ag 1024[no description available]low00alkylbenzene
benzethonium[no description available]low00alkylbenzene
isoxsuprine[no description available]low00alkylbenzene
nylidrin[no description available]low00alkylbenzene
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]low00alkylbenzene
octoxynol[no description available]low00alkylbenzene
tyrphostin a9[no description available]low00alkylbenzenegeroprotector
valethamate[no description available]low00alkylbenzene
xylometazoline[no description available]low00alkylbenzene
hydroxyphenamate[no description available]low00alkylbenzene
isoaminile[no description available]low00alkylbenzene
phenaglycodol[no description available]low00alkylbenzene
p-tert-amylphenol[no description available]low00alkylbenzene
2-tert-butylphenol[no description available]low00alkylbenzene
2,6-di-tert-butyl-4-hydroxymethylphenol[no description available]low00alkylbenzene
2,4-di-tert-butylphenol[no description available]low00alkylbenzene;
phenols		antioxidant;
bacterial metabolite;
marine metabolite
4-tert-butylbenzoic acid[no description available]low00alkylbenzene
cumene[no description available]low00alkylbenzene
ethylbenzene[no description available]low00alkylbenzene
n-propylbenzene[no description available]low00alkylbenzene
n-butylbenzene[no description available]low00alkylbenzene
proxazole[no description available]low00alkylbenzene
sec-butylbenzene[no description available]low00alkylbenzene
sulfurous acid, 2-(p-tert-butylphenoxy)-1-methylethyl 2-chloroethyl ester[no description available]low00alkylbenzene
4-tert-octylphenol[no description available]low00alkylbenzene
crufomate[no description available]low00alkylbenzene
isoxsuprine hydrochloride[no description available]low00alkylbenzene
4-propylphenol[no description available]low00alkylbenzene
promecarb[no description available]low00alkylbenzene
o-cymen-5-ol[no description available]low00alkylbenzene
butethamate citrate[no description available]low00alkylbenzene
2,6-di-tert-butylphenol[no description available]low00alkylbenzene;
phenols		antioxidant
lifibrol[no description available]low00alkylbenzene
ephedrine hydrochloride[no description available]low00alkylbenzene
simetride[no description available]low00alkylbenzene
fenoxazoline[no description available]low00alkylbenzene
tris-(2,4-di-tert-butylphenyl) phosphite[no description available]low00alkylbenzene
fenpropimorph[no description available]low00alkylbenzene
2-(n-myristoylamino)-1-phenyl-1-propanol[no description available]low00alkylbenzene
3-(2-hydroxy-4-(1,1-dimethylheptylphenyl)cyclohexan-1-ol)[no description available]low00alkylbenzene;
ring assembly
4-propylbenzoic acid[no description available]low00alkylbenzene
2-n-hexyl-5-n-propylresorcinol[no description available]low00alkylbenzene
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol[no description available]low00alkylbenzene
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]low00alkylbenzene
oxilofrine[no description available]low00alkylbenzene
2-[(dimethylamino)methyl]-4-methyl-6-(1-methylcyclohexyl)phenol[no description available]low00alkylbenzene;
ring assembly
1-(1-azepanyl)-2-(2-bromo-4-propan-2-ylphenoxy)ethanone[no description available]low00alkylbenzene
N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-2-methoxyacetamide[no description available]low00alkylbenzene
4-(4-tert-butylphenoxy)-N-(4,5-dihydrothiazol-2-yl)butanamide[no description available]low00alkylbenzene
2-(2-bromo-4-tert-butylphenoxy)-N-(2-furanylmethyl)acetamide[no description available]low00alkylbenzene
N-[[[2-(2-bromo-4-propan-2-ylphenoxy)-1-oxoethyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide[no description available]low00alkylbenzene
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-propan-2-ylphenyl) ester[no description available]low00alkylbenzene
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-tert-butylphenyl) ester[no description available]low00alkylbenzene
3-(4-tert-butylphenoxy)-N-(4,5-dihydrothiazol-2-yl)propanamide[no description available]low00alkylbenzene
2-[[2-[[5-(4-tert-butylphenyl)-2-methoxycarbonyl-3-thiophenyl]amino]-2-oxoethyl]thio]acetic acid[no description available]low00alkylbenzene
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol[no description available]low00alkylbenzene
N-(2-methoxycyclohexyl)-2,5-dimethylaniline[no description available]low00alkylbenzene
tinofedrine[no description available]low00alkylbenzene
fospropofol[no description available]low00alkylbenzene
cgp 13501[no description available]low00alkylbenzene
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol[no description available]low00alkylbenzene;
ring assembly
cgp 7930[no description available]low00alkylbenzene
nylidrin hydrochloride[no description available]low00alkylbenzene
methylbenzethonium chloride[no description available]low00alkylbenzene
tapentadol[no description available]low00alkylbenzene
o-demethyltramadol[no description available]low00alkylbenzene;
ring assembly
elsibucol[no description available]low00alkylbenzene
2-(4-butan-2-ylanilino)-3-pyridinecarbonitrile[no description available]low00alkylbenzene
oxaziclomefone[no description available]low00alkylbenzene
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Disease Models, Animal0low10
Fever, Zika0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10
Acute Disease0low10
Asthma0low10
Asthma, Bronchial0low10
Bronchial Asthma0low10
Bronchitis0low10
Cervical Dystonia0low10
Chronic Disease0low10
Chronic Illness0low10
Chronically Ill0low10
Disease Models, Animal0low10
Glial Cell Tumors0low10
Glioma0low10
Infections, Respiratory0medium21
Infections, Respiratory Tract0medium21
Infections, Upper Respiratory0medium21
Infections, Upper Respiratory Tract0medium21
Inflammation0low20
Innate Inflammatory Response0low20
Malignant Glioma0low10
Mixed Glioma0low10
Poisoning0low10
Respiratory Infections0medium21
Respiratory Tract Diseases0low10
Respiratory Tract Infections0medium21
Sensitivity and Specificity0low10
Spasmodic Torticollis0low10
Torticollis0low10
Torticollis, Intermittent0low10
Torticollis, Psychogenic0low10
Upper Respiratory Infections0medium21
Upper Respiratory Tract Infection0medium21
Upper Respiratory Tract Infections0medium21
Wryneck0low10

Research Highlights

Safety/Toxicity (1)

ArticleYear
[The use and safety of butamirate containing drops, syrup and depot tablets in Hungary].
Orvosi hetilap, Mar-27, Volume: 146, Issue: 13		2005
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

ArticleYear
Combination of large volume sample stacking with polarity switching and cyclodextrin electrokinetic chromatography (LVSS-PS-CDEKC) for the determination of selected preservatives in pharmaceuticals.
Talanta, May-01, Volume: 211		2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (3)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers.
International journal of clinical pharmacology and therapeutics, Volume: 35, Issue: 3		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (4)

ArticleYear
A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers.
British journal of clinical pharmacology, Volume: 78, Issue: 6		2014
[Butamyrate citrate in cough controlling].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, Volume: 35, Issue: 210		2013
Acute cervical dystonia after the first dose of butamirate citrate.
Pediatric emergency care, Volume: 29, Issue: 1		2013
Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers.
International journal of clinical pharmacology and therapeutics, Volume: 35, Issue: 3		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]